Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 9/20 | 0.39 |
| ▸ | INSR | P06213 | 7/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | NPM1 | P06748 | 7/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520446 | 0.86 | JAK2 (0.57) | JAK2ALKINSRCYP3A4NPM1 | |
| SCHEMBL522645 | 0.82 | JAK2 (0.45) | JAK2ALKINSRCYP3A4NPM1 | |
| SCHEMBL521852 | 0.81 | AURKA (0.42) | JAK2CYP3A4HSD11B1 | |
| SCHEMBL521590 | 0.80 | EGLN2 (0.40) | JAK2ALKINSRCYP3A4NPM1 | |
| SCHEMBL521834 | 0.79 | JAK2 (0.43) | JAK2ALKINSRCYP3A4NPM1 | |
| SCHEMBL519978 | 0.77 | MAPK1 (0.44) | JAK2ALKINSRCYP3A4NPM1 | |
| SCHEMBL520259 | 0.77 | EGLN2 (0.40) | JAK2ALKINSRCYP3A4NPM1 | |
| SCHEMBL521921 | 0.77 | JAK2 (0.47) | JAK2ALKINSRCYP3A4NPM1 | |
| SCHEMBL520199 | 0.76 | JAK2 (0.44) | JAK2ALKINSRCYP3A4NPM1 | |
| SCHEMBL521115 | 0.74 | ALK (0.41) | JAK2ALKINSRCYP3A4NPM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | JAK2 1/4885ALK 2/4885INSR 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.